Clinical trials
Diffuse Large B Cell Lymphoma clinical trials
Below are recruiting diffuse large b cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 377 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Tucson, ArizonaAges 18 years+ - NCT07519772RecruitingPhase 1/Phase 2
Testing MK-1045 for Hard-to-Treat Lymphoma
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT06919939RecruitingPhase 2
Epcoritamab and Loncastuximab for relapsed large B-cell lymphoma
This trial tests a combination of two targeted drugs (epcoritamab and loncastuximab tesirine) for people with large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors and improve outcomes.
Miami, FloridaAges 18 years+ - NCT03356054RecruitingPhase 1/Phase 2
Test drug for CD30-positive lymphoma after first treatment fails
This early-phase study tests a lymphoma treatment in adults whose diffuse large B-cell lymphoma (DLBCL) is “CD30-positive” and who didn’t respond well to first-line chemotherapy (like R-CHOP) or had an early relapse. It aims to see if the treatment can shrink the lymphoma and is safe enough to move forward.
RotterdamAges 18 years+ - NCT04824950Recruiting
Blood DNA test in newly diagnosed mediastinal large B-cell lymphoma
This study looks at how “circulating tumor DNA” in blood changes in people with newly diagnosed primary mediastinal large B-cell lymphoma. It may help doctors better monitor treatment response alongside standard PET/CT-guided care, which could improve follow-up decisions.
LyonAges 18 years+ - NCT03869619Recruiting
Real-life data study for adults with recent lymphoma
This study collects “real-world” health information about adults whose lymphoma was diagnosed within the last 6 months. It aims to better understand lymphoma types and how patients do over time, using data from everyday care rather than testing a new drug.
ArrasAges 18 years+ - NCT05040555Recruiting
Testing a new chemo plan for newly diagnosed high-burden lymphoma
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
Changchun, JilinAges 18–75 - NCT04670029RecruitingPhase 3
Testing an APA program to improve outcomes in large B-cell lymphoma
This Phase 3 trial studies whether an APA program (an added supportive program during care) can improve event-free survival for people with diffuse large B-cell lymphoma. It may help by supporting patients during standard first-line treatment so they do better over time.
BesançonAges 65 years+ - NCT04502394RecruitingPhase 1/Phase 2
Investigational drug combo for relapsed blood cancer
This trial combines two investigational drugs to see if they are safe and effective for patients with two types of blood cancer: diffuse large B-cell lymphoma (DLBCL) or chronic lymphocytic leukemia (CLL) that has come back or stopped responding to standard treatments. It may offer a new option when other treatments have not worked.
Goshen, IndianaAges 18 years+ - NCT05518383RecruitingPhase 4
Pediatric B-cell lymphoma treatment study using established care
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
Moscow, RFAges 1 day–18 years - NCT04442412RecruitingPhase 3
Prednisone and vitamin D before chemo for certain lymphomas
This Phase 3 study tests whether a short “pre-treatment” with prednisone, with or without vitamin D, can improve outcomes when followed by standard lymphoma chemo. It aims to see if adding vitamin D early can help older adults tolerate or benefit from treatment for specific lymphoma types.
Brescia, BSAges 65 years+ - NCT05659628RecruitingPhase 1
CD19 CAR-T plus PD-1 antibody for relapsed lymphoma
This Phase 1 study tests a new type of immune cell therapy (CD19 CAR-T) combined with an anti–PD-1 drug for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It aims to improve cancer control when standard treatments have not worked or the cancer has come back.
Hangzhou, ZhejiangAges 18–75 - NCT05648019RecruitingPhase 2
CD19 CAR T-cell therapy for tough B-cell blood cancers
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
SingaporeAges birth–70 years - NCT04920617RecruitingPhase 2
Vaccine plus pembrolizumab, with or without low-dose chemo
This Phase 2 study tests whether a cancer vaccine called DPX-Survivac, along with pembrolizumab (an immune medicine), can help shrink diffuse large B-cell lymphoma (DLBCL) that has come back or not responded. It also looks at whether adding intermittent low-dose cyclophosphamide (a low-dose chemotherapy) improves results.
Fountain Valley, CaliforniaAges 18 years+ - NCT05831865Recruiting
Testing best first-line stem cell transplant for aggressive lymphoma
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
Beijing, Beijing MunicipalityAges 18–70 - NCT05842707RecruitingPhase 1/Phase 2
Cord blood CAR cells for hard-to-treat B-cell lymphoma
This Phase 1/2 study tests cord blood–derived CAR NK cells that are designed to attack lymphoma cells marked with CD19 and/or CD70. It is for people whose B-cell non-Hodgkin lymphoma has come back or did not respond to prior treatment, including CAR-T when applicable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05933967RecruitingPhase 2
Orelabrutinib with R-CHOP for newly diagnosed lymphoma
This Phase 2 trial tests whether adding orelabrutinib to standard chemotherapy (R-CHOP) can improve treatment for people with newly diagnosed double-expressing diffuse large B-cell lymphoma. It’s intended for adults who are well enough to receive treatment and whose lymphoma is in the body (not in the brain/spinal fluid).
Nanchang, JiangxiAges 18–70 - NCT06081478RecruitingPhase 2
Targeted CAR-T cell therapy for advanced lymphoma or leukemia
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Beijing, Beijing MunicipalityAges 14–85 - NCT06176729RecruitingPhase 2
Pola-R2 for older, less fit adults with new DLBCL
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
Beijing, Beijing MunicipalityAges 70 years+ - NCT06180174RecruitingPhase 1
CD19-targeted CAR-T cells for relapsed B-cell lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07862010RecruitingEarly Phase 1
Study of GI001 for B-cell lymphoma and leukemia that has returned or not responded
This trial tests a new treatment called GI001 for people with B-cell lymphoma or B-cell leukemia that has come back or hasn't responded to previous treatments. It aims to see if GI001 can help when other options have failed, and it may be an option if you haven't had CAR-T therapy before.
Yunnan, KunmingAges 18–75 - NCT06321289RecruitingPhase 1/Phase 2
Donor T cell therapy for B-cell lymphoma
This trial tests a new type of therapy where specially designed donor T cells target your lymphoma. It's for people with certain B-cell non-Hodgkin lymphomas that have not responded to or returned after standard treatments. You might join if you meet the health and disease criteria listed below.
Beijing, Beijing MunicipalityAges 18–75 - NCT06339255Recruiting
Observational study on CAR-T therapy for lymphoma
This study observes patients with certain lymphomas who are already eligible for standard CAR-T cell therapy in Italy. It aims to gather real-world information about how these treatments work.
MilanAges 18 years+
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Diffuse Large B Cell Lymphoma trials by city
Studies with a site in or near these metro areas.
Diffuse Large B Cell Lymphoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for diffuse large b cell lymphoma?
- Yes. Clin2 currently lists 377 recruiting diffuse large b cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diffuse large b cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diffuse large b cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Refractory Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Large B-cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.